<DOC>
	<DOCNO>NCT01108185</DOCNO>
	<brief_summary>The aim post-marketing observational study ( PMOS ) describe relief symptom , tolerability compliance treatment Klacid®SR dose 1000 mg daily patient low respiratory tract infection patient acute exacerbation chronic bronchitis ( AECB ) mild community-acquired pneumonia ( CAP ) .</brief_summary>
	<brief_title>Evaluation Treatment With Klacid®SR Patients With Lower Respiratory Tract Infection</brief_title>
	<detailed_description>This PMOS conduct prospective , open-label , single-country , multicenter format . The investigational site consult room GPs ( general practitioner ) , pneumologists center experience treatment patient low respiratory tract infection , AECB ( acute exacerbation chronic bronchitis ) CAP ( mild community-acquired pneumonia ) . Since PMOS , Klacid®SR prescribe usual manner accordance term local market authorization regard dose , population indication well local guideline . The decision prescribe prescribe Klacid®SR would take prior entry subject study . Follow-up patient enable two patient visit period . Screening/Inclusion Visit perform decision start treatment Klacid®SR make . Inclusion patient study succeed day 0 ( S/I Visit ) . The Second Visit follow 10 - 16 day Screening/Inclusion Visit .</detailed_description>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Bronchitis</mesh_term>
	<mesh_term>Acute Disease</mesh_term>
	<mesh_term>Respiratory Tract Infections</mesh_term>
	<mesh_term>Bronchitis , Chronic</mesh_term>
	<mesh_term>Tracheitis</mesh_term>
	<criteria>Men , woman least 18 year old acute tracheitis , acute tracheobronchitis , acute bronchitis , mild communityacquired pneumonia acute exacerbation chronic bronchitis Patients know hypersensitivity macrolide antibiotic Patients document renal impairment ( creatinine clearance 30 ml/min ) . Patients document liver parenchyma impairment ( AST , ALT GMT &gt; 3x high level comparison norm ) Concomitant therapy follow drug : astemizole , cisapride , colchicine , pimozide , terfenadine ergotamine dihydroergotamine Pregnancy Breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>treatment Klacid®SR</keyword>
	<keyword>tracheitis</keyword>
	<keyword>tracheobronchitis</keyword>
	<keyword>bronchitis</keyword>
	<keyword>chronic bronchitis</keyword>
	<keyword>community-acquired pneumonia</keyword>
</DOC>